"Masoprocol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils.
| Descriptor ID |
D009637
|
| MeSH Number(s) |
D02.455.426.559.389.140.450.582 D02.455.426.559.389.657.166.550
|
| Concept/Terms |
Masoprocol- Masoprocol
- (R*,S*)-4,4'-(2,3-Dimethylbutane-1,4-diyl)bispyrocatechol
- Nordihydroguaiaretic Acid
- Nordihydroguaiaretic Acid, (R*,S*)-Isomer
- Dihydronorguaiaretic Acid
- meso-Nordihydroguaiaretic Acid
- Acid, meso-Nordihydroguaiaretic
- meso Nordihydroguaiaretic Acid
|
Below are MeSH descriptors whose meaning is more general than "Masoprocol".
Below are MeSH descriptors whose meaning is more specific than "Masoprocol".
This graph shows the total number of publications written about "Masoprocol" by people in this website by year, and whether "Masoprocol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Masoprocol" by people in Profiles.
-
Inhibition of AP-1 transcription activator induces myc-dependent apoptosis in HL60 cells. J Cell Biochem. 2004 Apr 01; 91(5):973-86.
-
Determination of binding constant of transcription factor myc-max/max-max and E-box DNA: the effect of inhibitors on the binding. Biochim Biophys Acta. 2004 Feb 24; 1670(3):217-28.
-
Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth. Exp Lung Res. 1998 Jul-Aug; 24(4):617-28.
-
Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest. 1996 Feb 01; 97(3):806-13.